insphero公司聯(lián)合蘇黎世大學(xué)的骨科研究實(shí)驗(yàn)室、化學(xué)和生物化學(xué)研究所，應(yīng)用insphero 3D細(xì)胞懸滴培養(yǎng)板，構(gòu)建3D骨肉瘤模型。

文章“An in vitro osteosarcoma 3D microtissue model for drug development”于2014年11月10號(hào)發(fā)表于 Journal of Biotechnology上

（鏈接地址：http://www.ncbi.nlm.nih.gov/pubmed/25234575）

作者介紹：

Markus Rimann^a, 1, Sandra Laternser^a, 1, Ana Gvozdenovic^b, Roman Muff^b,   Bruno Fuchs^b, Jens M. Kelm^c, Ursula Graf-Hausner^a, , 

^a Institute of Chemistry and Biological Chemistry (ICBC), Zurich University of Applied Sciences, Waedenswil, Switzerland

^b Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Switzerland

^c InSphero AG, Schlieren, Switzerland

文章亮點(diǎn)：

1.Microtissues (3D) from three different osteosarcoma cell lines were developed.

  取三種不同的骨肉瘤細(xì)胞系（SaOS-2、HOS和MG-63細(xì)胞），采用insphero 3D細(xì)胞懸滴培養(yǎng)板構(gòu)建3D骨肉瘤微組織

2. Microtissues from patient-derived osteosarcoma were produced.

  骨肉瘤細(xì)胞系（SaOS-2、HOS和MG-63細(xì)胞），均取自成骨肉瘤和軟骨肉瘤病人

3.Inherent osteosarcoma tissue heterogeneity was shown with different microtissues.

  不同的微組織，會(huì)顯示出骨肉瘤固有的組織異質(zhì)性

4.Five drug responses were analysed in 3D showing differences compared to 2D.

  用五種藥物（阿霉素、順鉑、牛磺羅定、培美曲塞、紫杉醇）對(duì)3D骨肉瘤微組織用藥，實(shí)驗(yàn)結(jié)果是不同于常規(guī)2D細(xì)胞培養(yǎng)的

總結(jié)：

The 3D microtissues reflect the tissue heterogeneity of OS and are potential suitable tools for drug development towards personalised medicine

3D微組織能夠反映出骨肉瘤（OS）固有的組織異質(zhì)性，它將成為藥物開(kāi)發(fā)以及走向個(gè)人化醫(yī)療過(guò)程中的有潛力工具。